Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer
Charline Ogier(Fox Chase Cancer Center), Christel Larbouret(Inserm), Nelly Pirot(Inserm), Marta Jarlier(Institut de Recherche en Cancérologie de Montpellier), Pierre Sicard(Centre National de la Recherche Scientifique), Bruno Robert(Inserm), Pierre‐Emmanuel Colombo(Inserm), Thierry Chardès(Centre National de la Recherche Scientifique), Nadège Gaborit(Inserm), Martine Pugnière(Inserm), Pierre Martineau(Université de Montpellier), Corinne Bousquet(Centre National de la Recherche Scientifique), André Pèlegrin(Inserm), Gaëlle Thomas(Université de Montpellier), Céline Gongora(Centre National de la Recherche Scientifique), Nadia Vié(Inserm), Véronique Garambois(Inserm), Lucile Canterel-Thouennon(Inserm)
Cited by 57
Related Papers
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors
|British Journal of Pharmacology|2021|488
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors
|British Journal of Pharmacology|2023|390
Autoregulation of pituitary corticotroph SOCS-3 expression: Characterization of the murine SOCS-3 promoter
|Proceedings of the National Academy of Sciences|1999|290
Inter‐ and intra‐tumoural heterogeneity in cancer‐associated fibroblasts of human pancreatic ductal adenocarcinoma
|The Journal of Pathology|2018|284